{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '13.7.', 'Safety Analysis', '100', '13.7.1.', 'Analysis of the Key Secondary Safety Endpoint', '101', '13.7.1.1.', 'Peripheral Neuropathy Events', '101', '13.7.2.', 'Analyses of the Non-Key Secondary Safety Endpoints', '101', '13.7.2.1.', 'Study Treatment Exposure', '101', '13.7.2.2.', 'Adverse Events', '101', '13.7.2.3.', 'Clinical Laboratory Data', '102', '13.7.2.4.', 'Vital Signs and Physical Examinations', '102', '13.7.2.5.', 'Electrocardiogram', '102', '13.7.2.6.', 'Ophthalmological Examinations', '102', '13.7.2.7.', 'Concomitant Medications', '103', '13.8.', 'QoL Analyses', '103', '13.9.', 'Changes in the Conduct of the Study or Planned Analyses', '103', '14.', 'ADMINISTRATIVE MATTERS', '104', '14.1.', 'Regulatory and Ethical Compliance', '104', '14.2.', 'Ethics Committees', '104', '14.3.', 'Regulatory Authority Approval', '104', '14.4.', 'Protocol Adherence', '104', '14.5.', 'Amendments to the Protocol', '104', '14.6.', 'Informed Consent', '104', '14.7.', 'Patient Confidentiality and Disclosure', '105', '14.8.', 'Study Documentation, Data Collection and Storage, and Study Monitoring', 'and Auditing Procedures', '105', '14.8.1.', 'Study Documentation, Record Keeping, and Retention of Documents', '105', '14.8.2.', 'Study Monitoring and Auditing Procedures', '106', '14.9.', 'Disclosure of Information', '106', '14.10.', 'Discontinuation of the Study', '106', '14.11.', 'Study Report and Publication Policy', '107', '15.', 'LIST OF REFERENCES', '108', 'APPENDIX 1. PROTOCOL AMENDENT: RATIONALES AND SUMMARY OF', 'CHANGES', '112', 'Confidential', 'Page 10', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'LIST OF TABLES', 'Table 1:', 'Abbreviations and Definitions of Terms', '12', 'Table 2:', 'Schedule of Assessments for Study KCP-330-023', '22', 'Table 3:', 'Unique Visits Required for Crossover to SVdX or SdX: Separate OR', 'Combined Visits', '28', 'Table 4:', 'SVd Arm: Schedule of Visits for In-clinic Dosing and MM Evaluations', '29', 'Table 5:', 'Vd Arm: Schedule of Visits for In-clinic Dosing and MM Evaluations', '29', 'Table 6:', 'SVdX Treatment: Schedule of Visits for In-clinic Dosing and MM', 'Evaluations', '30', 'Table 7:', 'SdX Treatment: Schedule of Visits for In-clinic Dosing and MM Evaluations', '30', 'Table 8:', 'SVd Arm/SVdX Treatment Dose Schedule; 5-Week (35-Day) Cycle', '31', 'Table 9:', 'Dose Schedule for Vd Arm Cycles 1 through 8; 3-Week (21-day) Cycle', '32', 'Table 10: Dose Schedule for Vd Arm Cycles 9; 5-Week (35-day) Cycle', '32', 'Table 11:', 'Dose Schedule for SdX Patients; 5-Week (35-Day) Cycle', '33', 'Table 12: KCP-330-017 Best Responses in Evaluable SVd Patients as of 05 June 2018', '39', 'Table 13: In-clinic Dosing and MM Evaluations', '48', 'Table 14: Revised International Staging System for Multiple Myeloma', '56', 'Table 15: Pre-specified Dose Modifications for AEs Related to Selinexor', '63', 'Table 16: Supportive Care and Selinexor Dose Adjustment Guidelines for AEs Related', 'to Selinexor', '64', 'Table 17:', 'International Myeloma Working Group Response Criteria, Myeloma', '(Kumar, 2016)', '74', 'Table 18: Collection Time Points for Bortezomib and Selinexor PK', '80', 'Table 19: Clinical Laboratory Tests', '83', 'LIST OF FIGURES', 'Figure 1: Study KCP-330-023 Overview', '34', 'Confidential', 'Page 11', 'Version 4.0']\n\n###\n\n", "completion": "END"}